BioAtla Inc. (BCAB) PT Raised to $8 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts BCAB Hot Sheet
Price: $1.74 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on BioAtla Inc. (NASDAQ: BCAB) to $8.00 (from $4.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
- Altria (MO) PT Raised to $83 at UBS
- Roblox Corp. (RBLX) PT Lowered to $32 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
